Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 17Melanoma 3Glioma 3Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Multiple Endocrine Neoplasia Type 1 2Diffuse Intrinsic Pontine Glioma 2Thymus Neoplasms 1Teratoma 1Solid Tumors Harboring a BRAF V600 Mutation 1Rhabdoid Tumor 1Osteitis Deformans 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Neuroblastoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Mesothelioma 1Medulloblastoma 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Glioblastoma 1Familial ependymoma 1Fallopian Tube Neoplasms 1Estrogen Receptor and/or Progesterone Receptor Positive 1Cystadenocarcinoma, Serous 1Carcinoma, Hepatocellular 1

Interventions

ribociclib 1Pharmacogenomic Variants 1Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Estrogen Receptor and/or Progesterone Receptor Positive × ribociclib × Clear all
NCT03477396 2024-02-20

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

City of Hope Medical Center

Phase 2 Completed
2 enrolled 13 charts
Breast

Estrogen Receptor and/or Progesterone Receptor Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡